> Product Benefits
Product Benefits
Non-adjuvanted PUREVAX® Recombinant Leukemia Vaccine and the VET JET™ transdermal
vaccination system provide enhanced immune response1 through targeted antigen presentation.
Non-adjuvanted
PUREVAX Recombinant Leukemia Vaccine is made without the use of adjuvants, the chemical
additives that have been associated with the risk of potential injection site reactions.2
Made using recombinant technology
- Uses only the specific genetic material from FeLV necessary to induce immunity
- Vectored by the canarypox virus, which cannot replicate in mammals3,4
- Stimulates humoral and cell-mediated immune response4
Targeted antigen presentation to provide effective immunity with lower vaccine volume
(0.25 mL per dose).
The VET JET transdermal vaccination system exposes more of the effective antigen-presenting cells of the dermis (dendritic cells)to the antigen than the traditional needle injections.
Manufactured and supported by Merial, the global leader in recombinant vaccines.
1Data on file at Merial.
2Macy DW, Hendrick MJ. The potential role of inflammation in the development of postvaccinal sarcoma in cats.
Vet Clin North Am Small Animal Pract 1996;26(1):103-109.
3Plotkin SA, Cadoz M, et al. The Safety and Use of Canarypox Vectored Vaccines. Del Bio Stand. 1995;165-170.
4Poulet H, Brunet S, et al. Efficacy of a canarypox virus-vectored vaccine against feline leukemia. The Veterinary Record. 2003;141-145.
Home > PUREVAX > Product Benefits
We invite you to discover more great products, solutions and services offered by Merial.
